DK1272058T3 - Formuleringer til spædbørn indeholdende langkædede polyumættede fedtsyrer og anvendelser deraf - Google Patents
Formuleringer til spædbørn indeholdende langkædede polyumættede fedtsyrer og anvendelser deraf Download PDFInfo
- Publication number
- DK1272058T3 DK1272058T3 DK01928487.6T DK01928487T DK1272058T3 DK 1272058 T3 DK1272058 T3 DK 1272058T3 DK 01928487 T DK01928487 T DK 01928487T DK 1272058 T3 DK1272058 T3 DK 1272058T3
- Authority
- DK
- Denmark
- Prior art keywords
- dha
- infants
- formula
- infant
- months
- Prior art date
Links
- 235000013350 formula milk Nutrition 0.000 title description 188
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 title description 15
- 235000015097 nutrients Nutrition 0.000 claims description 65
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 47
- 229930195729 fatty acid Natural products 0.000 claims description 47
- 239000000194 fatty acid Substances 0.000 claims description 47
- 150000004665 fatty acids Chemical class 0.000 claims description 47
- 230000000007 visual effect Effects 0.000 claims description 42
- 238000011161 development Methods 0.000 claims description 39
- 230000018109 developmental process Effects 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 39
- 235000020256 human milk Nutrition 0.000 claims description 30
- 210000004251 human milk Anatomy 0.000 claims description 29
- 230000007472 neurodevelopment Effects 0.000 claims description 22
- 235000016709 nutrition Nutrition 0.000 claims description 21
- 235000019577 caloric intake Nutrition 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 11
- 230000037396 body weight Effects 0.000 claims description 10
- 230000008140 language development Effects 0.000 claims description 10
- 230000008111 motor development Effects 0.000 claims description 10
- 230000002028 premature Effects 0.000 claims description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 139
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 138
- 230000035611 feeding Effects 0.000 description 84
- 230000012010 growth Effects 0.000 description 59
- 241000251468 Actinopterygii Species 0.000 description 58
- 235000019688 fish Nutrition 0.000 description 58
- 239000003921 oil Substances 0.000 description 40
- 235000019198 oils Nutrition 0.000 description 38
- 102100033609 Kelch domain-containing protein 2 Human genes 0.000 description 36
- 229920000106 Liquid crystal polymer Polymers 0.000 description 36
- 230000002538 fungal effect Effects 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 30
- 239000002002 slurry Substances 0.000 description 28
- 238000000034 method Methods 0.000 description 27
- 150000002632 lipids Chemical class 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 230000004304 visual acuity Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 235000005911 diet Nutrition 0.000 description 15
- 210000003128 head Anatomy 0.000 description 15
- 230000035764 nutrition Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000013019 agitation Methods 0.000 description 13
- 230000000763 evoking effect Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000002243 precursor Substances 0.000 description 12
- 230000009469 supplementation Effects 0.000 description 12
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 208000018773 low birth weight Diseases 0.000 description 11
- 231100000533 low birth weight Toxicity 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
- 235000020778 linoleic acid Nutrition 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 235000010469 Glycine max Nutrition 0.000 description 9
- 235000021342 arachidonic acid Nutrition 0.000 description 9
- 230000000378 dietary effect Effects 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 6
- 230000001149 cognitive effect Effects 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000010365 information processing Effects 0.000 description 6
- 239000012263 liquid product Substances 0.000 description 6
- 230000035800 maturation Effects 0.000 description 6
- 235000020601 preterm formula Nutrition 0.000 description 6
- 235000021055 solid food Nutrition 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 235000004626 essential fatty acids Nutrition 0.000 description 5
- 230000036630 mental development Effects 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 244000060011 Cocos nucifera Species 0.000 description 4
- 235000013162 Cocos nucifera Nutrition 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010051606 Necrotising colitis Diseases 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical class CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 4
- -1 nitrogen containing compound Chemical class 0.000 description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 4
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 244000020518 Carthamus tinctorius Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 229960004232 linoleic acid Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- 241000199914 Dinophyceae Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000020547 Peroxisomal disease Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000004350 Strabismus Diseases 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000007833 carbon precursor Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 230000008133 cognitive development Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000008236 heating water Substances 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 238000013105 post hoc analysis Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000013102 re-test Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical class CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 239000001195 (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid Substances 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UABIXNSHHIMZEP-UHFFFAOYSA-N 2-[2-[(dimethylamino)methyl]phenyl]sulfanyl-5-methylaniline Chemical compound CN(C)CC1=CC=CC=C1SC1=CC=C(C)C=C1N UABIXNSHHIMZEP-UHFFFAOYSA-N 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 208000032135 Birth Weight Diseases 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 241000199912 Crypthecodinium cohnii Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- SPJOZZSIXXJYBT-UHFFFAOYSA-N Fenson Chemical compound C1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 SPJOZZSIXXJYBT-UHFFFAOYSA-N 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 208000032754 Infant Death Diseases 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000235575 Mortierella Species 0.000 description 1
- 241000907999 Mortierella alpina Species 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000197220 Pythium insidiosum Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010041092 Small for dates baby Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 201000004525 Zellweger Syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 238000011872 anthropometric measurement Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 201000001272 cocaine abuse Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000008132 psychomotor development Effects 0.000 description 1
- 230000035802 rapid maturation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000004517 retinal physiology Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 235000021076 total caloric intake Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pediatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19697000P | 2000-04-13 | 2000-04-13 | |
| PCT/US2001/011964 WO2001078530A2 (en) | 2000-04-13 | 2001-04-12 | Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1272058T3 true DK1272058T3 (da) | 2015-09-21 |
Family
ID=22727498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01928487.6T DK1272058T3 (da) | 2000-04-13 | 2001-04-12 | Formuleringer til spædbørn indeholdende langkædede polyumættede fedtsyrer og anvendelser deraf |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US6596302B2 (da) |
| EP (1) | EP1272058B1 (da) |
| JP (2) | JP2004518609A (da) |
| KR (1) | KR100793048B1 (da) |
| CN (1) | CN1436048A (da) |
| AR (1) | AR028331A1 (da) |
| AU (1) | AU2001255337A1 (da) |
| BR (1) | BR0107069A (da) |
| CA (1) | CA2405822C (da) |
| DK (1) | DK1272058T3 (da) |
| ES (1) | ES2544853T3 (da) |
| HK (1) | HK1053247A1 (da) |
| IL (2) | IL151970A0 (da) |
| MX (1) | MXPA02010085A (da) |
| SA (1) | SA02220638B1 (da) |
| WO (1) | WO2001078530A2 (da) |
Families Citing this family (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19836339B4 (de) | 1998-08-11 | 2011-12-22 | N.V. Nutricia | Kohlenhydratmischung |
| US6596302B2 (en) * | 2000-04-13 | 2003-07-22 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof |
| EP1178103A1 (en) * | 2000-08-02 | 2002-02-06 | Dsm N.V. | Purifying crude pufa oils |
| US6818392B2 (en) | 2000-12-06 | 2004-11-16 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
| US6648864B2 (en) | 2000-12-12 | 2003-11-18 | The Procter & Gamble Company | Array of disposable absorbent article configurations and merchandise display system for identifying disposable absorbent article configurations for wearers |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| EP2163256B1 (en) | 2001-05-11 | 2015-09-02 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US20040048926A1 (en) * | 2002-03-15 | 2004-03-11 | Hoffman Dennis Robert | Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months |
| FR2839887A1 (fr) * | 2002-05-22 | 2003-11-28 | Synergia | Nouvelles compositions nutraceutiques et pharmaceutiques et leurs utilisations |
| US20040013787A1 (en) * | 2002-06-28 | 2004-01-22 | Theuer Richard C. | Fat compositions for infant formula and methods therefor |
| TW200412942A (en) * | 2002-08-06 | 2004-08-01 | Abbott Lab | Appetite control method |
| DK1549158T3 (da) * | 2002-10-10 | 2009-04-14 | Wyeth Corp | Babynæringsmiddelsammensætning indeholdende nukleotider |
| US20050175759A1 (en) * | 2004-02-09 | 2005-08-11 | Atul Singhal | Newborn infant formulas and feeding methods |
| US8815279B2 (en) * | 2003-02-10 | 2014-08-26 | University College London | Baby feeding formula and system |
| US6753350B1 (en) | 2003-03-24 | 2004-06-22 | Bristol-Myers Squibb Company | Method to reduce the incidence of intraventricular hemorrhage in preterm infants |
| US7951410B2 (en) | 2003-04-14 | 2011-05-31 | Mead Johnson Nutrition Company | Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid |
| US20040214791A1 (en) * | 2003-04-25 | 2004-10-28 | Nancy Auestad | High lactose infant nutrition formula |
| DE602004021596D1 (de) * | 2003-06-23 | 2009-07-30 | Nestec Sa | Säuglingsnährpräparat oder folgemilch |
| PL1638415T3 (pl) * | 2003-06-23 | 2011-05-31 | Nestec Sa | Preparat dla niemowląt lub preparat pochodny |
| WO2005000040A1 (en) * | 2003-06-24 | 2005-01-06 | University Of Kansas Medical Center | Infant formula |
| RU2332445C2 (ru) * | 2003-07-09 | 2008-08-27 | Джей-Ойл Миллз, Инк. | Антиоксидантная жировая или масляная композиция со стабильным вкусом |
| CA2531236C (en) * | 2003-07-21 | 2012-01-17 | Unilever Plc | Aiding of cognitive function |
| CA2436650A1 (en) * | 2003-08-06 | 2005-02-06 | Naturia Inc. | Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses |
| IL158555A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Human breast milk lipid mimetic as dietary supplement |
| US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
| SE0303513D0 (sv) * | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| US9040075B2 (en) * | 2003-12-19 | 2015-05-26 | Abbott Laboratories | Method of increasing lean body mass and reducing body fat mass in infants |
| EP1597978A1 (en) | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
| US8252769B2 (en) | 2004-06-22 | 2012-08-28 | N. V. Nutricia | Intestinal barrier integrity |
| CN101693103B (zh) * | 2004-06-22 | 2013-04-10 | 努特里希亚公司 | 肠屏障完整性的改进 |
| ES2253089B1 (es) * | 2004-07-16 | 2007-08-16 | Berthol Victor Laboratorios Ordesa, S.L. | Complemento nutraceutico para la preparacion de leches infantiles. |
| JP5160229B2 (ja) | 2004-09-30 | 2013-03-13 | モノソル・アールエックス・エルエルシー | 均一の成分を有する多層フィルム |
| EP1656839A1 (en) * | 2004-11-11 | 2006-05-17 | N.V. Nutricia | Nutrition containing lipid blend |
| EP3100616B1 (en) * | 2004-12-30 | 2020-02-12 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a growing animal |
| CA2537452C (en) * | 2005-03-09 | 2013-12-24 | Abbott Laboratories | Concentrated human milk fortifier liquid |
| US20060233915A1 (en) * | 2005-04-15 | 2006-10-19 | Bristol-Myers Squibb Company | Liquid nutritional product to supplement human milk |
| HUE031206T2 (en) | 2005-05-23 | 2017-06-28 | Massachusetts Inst Technology | Formulations and methods of application containing PUFA |
| US9179702B2 (en) | 2005-07-13 | 2015-11-10 | Abbott Laboratories | Liquid nutritional compositions containing unsaturated fatty acids |
| WO2007012069A2 (en) * | 2005-07-20 | 2007-01-25 | Brophy James S | Modification of particle morphology to improve product functionality |
| PL1940248T3 (pl) * | 2005-10-05 | 2010-05-31 | Nestec Sa | Zastosowanie odżywczej formulacji do promowania doganiania wzrostu |
| EP1776877A1 (en) | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
| US7829126B2 (en) | 2005-10-26 | 2010-11-09 | Abbott Laboratories | Infant formulas containing docosahexaenoic acid and lutein |
| US20070166354A1 (en) | 2005-10-26 | 2007-07-19 | Bridget Barrett-Reis | Method of reducing the risk of retinopathy of prematurity in preterm infants |
| US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
| WO2008054192A1 (en) * | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Use of nutritional compositions for preventing disorders |
| ATE509624T1 (de) | 2005-12-23 | 2011-06-15 | Nutricia Nv | Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz |
| DE602007008062D1 (de) * | 2006-01-31 | 2010-09-09 | Nestec Sa | Nährstoffzusammensetzung für säuglinge mit niedrigem geburtsgewicht |
| US7770729B2 (en) * | 2006-05-01 | 2010-08-10 | The Procter & Gamble Company | Array of multi-staged cleaning wipes |
| US9185922B2 (en) | 2006-06-02 | 2015-11-17 | University Of Guelph | Dairy product |
| US20070280998A1 (en) * | 2006-06-02 | 2007-12-06 | Larry Milligan | Dairy product |
| US20110183050A1 (en) * | 2006-07-20 | 2011-07-28 | Brophy James S | Modification of particle morphology to improve product functionality |
| ATE510460T1 (de) * | 2007-05-18 | 2011-06-15 | Mead Johnson Nutrition Co | Gesäuertes flüssiges muttermilch-ergänzungsmittel |
| US7959621B2 (en) | 2007-07-24 | 2011-06-14 | The Procter & Gamble Company | Array of disposable absorbent articles having a sequence of graphics corresponding to a wearer's stages of development |
| US20090197955A1 (en) * | 2008-01-31 | 2009-08-06 | Monsanto Company | Methods of improving dha deposition and related function and/or development |
| CN101584364B (zh) * | 2008-05-22 | 2012-11-21 | 内蒙古伊利实业集团股份有限公司 | 含有益智因子组合的液态乳制品及其制备方法 |
| BRPI0909972A2 (pt) | 2008-06-19 | 2015-08-25 | Unilever Nv | ''emulsão comestível'' |
| EP2346355B1 (en) * | 2008-09-02 | 2019-12-04 | N.V. Nutricia | Nutritional compositions with large diameter lipid globules with a coating comprising polar lipids |
| WO2010068086A1 (en) | 2008-12-11 | 2010-06-17 | N.V. Nutricia | Nutritional compositions with large lipid globule size |
| CN102271534B (zh) * | 2009-01-19 | 2014-07-09 | 雀巢产品技术援助有限公司 | 婴儿用营养组合物 |
| WO2010110649A1 (en) * | 2009-03-24 | 2010-09-30 | N.V. Nutricia | Stage 1 and stage 2 infant formula |
| US9149452B2 (en) * | 2009-04-20 | 2015-10-06 | Women's & Children's Health Research Institute Inc. | Methods and compositions for promoting the neurological development of an infant |
| AU2009201540B2 (en) * | 2009-04-20 | 2015-07-09 | South Australian Health And Medical Research Institute Limited | Methods and compositions for promoting the neurological development of an infant |
| WO2010134800A1 (en) * | 2009-05-19 | 2010-11-25 | N.V. Nutricia | Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution |
| DK2496092T3 (da) * | 2009-11-03 | 2018-07-16 | Dsm Ip Assets Bv | Sammensætning med celler og en polyumættet fedtsyre med mindst 20 carbonatomer (lc-pufa) |
| WO2011115476A1 (en) | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
| WO2012044155A1 (en) * | 2010-09-28 | 2012-04-05 | N.V. Nutricia | Fat composition for programming immune response |
| US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
| SG190087A1 (en) | 2010-11-02 | 2013-06-28 | Abbott Lab | Stable concentrated liquid human milk fortifier |
| WO2012092086A1 (en) * | 2010-12-29 | 2012-07-05 | Abbott Laboratories | Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child |
| US20160198753A1 (en) | 2012-12-18 | 2016-07-14 | Abbott Laboratories | Liquid concentrated human milk fortifier containing hypoallergenic protein and lutein |
| AP2015008623A0 (en) * | 2013-02-19 | 2015-07-31 | Tetra Laval Holdings & Finance | Process and assembly for recombining a food product |
| RU2654739C2 (ru) * | 2013-04-10 | 2018-05-22 | Нестек С.А. | Детская смесь с низким содержанием mcfa в определенных пропорциях и относительно высоким содержанием жирных кислот и ее применение в стимуляции здорового становления когнитивной функции у грудных детей |
| RU2662282C2 (ru) | 2013-11-01 | 2018-07-25 | Н.В. Нютрисиа | Липидная композиция для улучшения состава тела во время догоняющего роста |
| WO2015075069A1 (en) * | 2013-11-22 | 2015-05-28 | Tetra Laval Holdings & Finance S.A. | Process and assembly for formulating a food product |
| EP3079500B1 (en) * | 2013-12-12 | 2019-06-19 | Nestec S.A. | Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children |
| ES2725610T3 (es) * | 2013-12-12 | 2019-09-25 | Nestle Sa | Composiciones lácteas sintéticas que comprenden ácidos grasos poliinsaturados (PUFAS) para fomentar el establecimiento saludable de la función cognitiva en lactantes y niños varones y hembras |
| MX2016014570A (es) | 2014-05-08 | 2017-02-20 | Procter & Gamble | Siluetas de longitud a cintura de conjuntos y articulos absorbentes desechables para adultos. |
| JP6651503B2 (ja) | 2014-05-08 | 2020-02-19 | ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ | パッケージの群 |
| WO2015171378A1 (en) | 2014-05-08 | 2015-11-12 | The Procter & Gamble Company | Hip to waist silhouettes of adult disposable absorbent articles and arrays |
| EP3139884B1 (en) | 2014-05-08 | 2021-05-26 | The Procter & Gamble Company | Waist to side silhouettes of adult disposable absorbent articles and arrays |
| WO2015171384A1 (en) | 2014-05-08 | 2015-11-12 | The Procter & Gamble Company | Length to side silhouettes of adult disposable absorbent articles and arrays |
| US10034801B2 (en) | 2014-10-03 | 2018-07-31 | The Procter & Gamble Company | Adult disposable absorbent articles and arrays comprising improved product lengths |
| WO2016057818A1 (en) * | 2014-10-08 | 2016-04-14 | Abbott Laboratories | Nutritional compositions comprising an oxidizable component and water-soluble plant extract |
| WO2016057777A1 (en) | 2014-10-09 | 2016-04-14 | The Procter & Gamble Company | Length-to-side and hip-to-waist silhouettes of adult disposable absorbent articles and arrays |
| US10864117B2 (en) | 2014-10-09 | 2020-12-15 | The Procter & Gamble Company | Length-to-waist and hip-to-side silhouettes of adult disposable absorbent articles and arrays |
| WO2016086128A1 (en) | 2014-11-25 | 2016-06-02 | Abbott Laboratories | Method of improving visual processing, visual acuity, or both by administering compositions comprising rrr-alpha-tocopherol and carotenoid to infants |
| EP3244855B1 (en) | 2015-01-16 | 2020-07-29 | The Procter and Gamble Company | Adult disposable absorbent articles and arrays of said articles comprising absorbent cores having channels |
| JP2016216444A (ja) * | 2015-05-20 | 2016-12-22 | 国立大学法人広島大学 | 自然免疫系炎症抑制剤、食品組成物、食品添加物、及び、自然免疫系抑制剤のスクリーニング方法 |
| US10449099B2 (en) | 2015-06-25 | 2019-10-22 | The Procter & Gamble Company | Adult disposable absorbent articles and arrays of said articles comprising improved capacity profiles |
| EP3361885B1 (en) | 2015-10-15 | 2019-05-29 | N.V. Nutricia | Infant formula with special lipid architecture for promoting healthy growth |
| US10583054B2 (en) | 2015-11-06 | 2020-03-10 | The Procter & Gamble Company | Disposable absorbent article silhouettes and silhouette arrays |
| WO2017176108A1 (en) * | 2016-04-04 | 2017-10-12 | N.V. Nutricia | Method for improving language skills in children with suspected or confirmed cerebral palsy or children at increased risk thereof |
| EP3439647B1 (en) | 2016-04-04 | 2023-03-22 | N.V. Nutricia | Composition for use in reducing or preventing global developmental delay in children |
| BR112018071493A2 (pt) * | 2016-04-18 | 2019-02-19 | N.V. Nutricia | usos de ácido linoleico (la) e ácido alfa-linolênico (ala) na fabricação de uma composição nutricional, composição nutricional, método para prevenir declínio no funcionamento cognitivo induzido e método para prevenir redução na neurogênese induzida por estresse precoce |
| JP2019519487A (ja) | 2016-05-05 | 2019-07-11 | アクエスティブ セラピューティクス インコーポレイテッド | 送達増強エピネフリン組成物 |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| WO2018104512A1 (en) | 2016-12-09 | 2018-06-14 | N.V. Nutricia | Nutritional composition for improving cell membranes |
| CA3066361A1 (en) | 2017-06-07 | 2018-12-13 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
| EP3644927A1 (en) | 2017-06-30 | 2020-05-06 | The Procter and Gamble Company | Length-to-hip and length-to-waist silhouettes of disposable absorbent articles and arrays |
| JP2020524034A (ja) | 2017-06-30 | 2020-08-13 | ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ | ボクサーブリーフ型使い捨て吸収性物品及び群の臀部対側部シルエット |
| WO2019006316A1 (en) | 2017-06-30 | 2019-01-03 | The Procter & Gamble Company | SILHOUETTES LENGTH-SIDE FOR DISPOSABLE ABSORBENT ARTICLES OF BIKINI TYPE / SLIP LOW SIZE AND ASSEMBLIES |
| WO2019006290A1 (en) | 2017-06-30 | 2019-01-03 | The Procter & Gamble Company | SILHOUETTES LENGTH-ON-THE-SIDE OF DISPOSABLE ABSORBENT ARTICLES OF TYPE CALEÇON SHORT / BOYSHORT, AND LOTS |
| US11432971B2 (en) | 2017-06-30 | 2022-09-06 | The Procter & Gamble Company | Hip-to-side and waist-to-side silhouettes for bikini/low rise brief type disposable absorbent articles and arrays |
| US11511103B2 (en) | 2017-11-13 | 2022-11-29 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
| CN112004563B (zh) | 2018-02-01 | 2024-08-06 | 施菲姆德控股有限责任公司 | 血管内血泵以及使用和制造方法 |
| WO2021011473A1 (en) | 2019-07-12 | 2021-01-21 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of manufacture and use |
| WO2021016372A1 (en) | 2019-07-22 | 2021-01-28 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
| US11724089B2 (en) | 2019-09-25 | 2023-08-15 | Shifamed Holdings, Llc | Intravascular blood pump systems and methods of use and control thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670285A (en) | 1982-08-06 | 1987-06-02 | The University Of Toronto Innovations Foundation | Infant formula |
| DE3603000A1 (de) | 1986-01-31 | 1987-08-06 | Milupa Ag | Neue polyensaeure-reiche fettmischung und deren verwendung bei der herstellung von saeuglingsnahrungen |
| ES2033193B1 (es) * | 1990-10-30 | 1994-01-16 | Ganadera Union Ind Agro | Mezcla grasa para nutricion infantil y de adultos. |
| FR2668798B1 (fr) | 1990-11-02 | 1994-10-14 | Renault | Moteur deux temps. |
| US5658767A (en) | 1991-01-24 | 1997-08-19 | Martek Corporation | Arachidonic acid and methods for the production and use thereof |
| ZA92452B (en) | 1991-01-24 | 1992-10-28 | Martek Corp | Microbial oil mixtures and uses thereof |
| US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
| FR2721481B1 (fr) | 1994-06-27 | 1996-09-06 | Inst Rech Biolog Sa | Nouvelles compositions diététiques à base de phospholipides et leur utilisation comme complément nutritionnel. |
| EP0784437B1 (de) | 1994-10-05 | 1998-07-08 | MILUPA GmbH & Co. KG | Phospholipidhaltige fettmischung mit lcp-fettsäuren |
| JP3792309B2 (ja) | 1996-08-30 | 2006-07-05 | サントリー株式会社 | 不飽和脂肪酸含有油脂の製造方法 |
| ID22744A (id) * | 1997-02-21 | 1999-12-09 | Abbott Lab Cs | Metoda dan komposisi untuk mengurangi pengaruh dari nekrotisasi enterkolitis |
| ID23411A (id) | 1997-03-27 | 2000-04-20 | Bristol Myers Squibb Co | Penggunaan asam dokosaheksanoat dan asam arakidonat yang meningkatkan pertumbuhan bayi belum cukup bulan |
| SA98190002B1 (ar) | 1997-03-28 | 2006-06-20 | ذي يونيفيرسيتي اوف تننيسي ريسيرش كوربوريشن | استخدام أحماض دهنية تحتوي على عدة روابط غير مشبعة polyunsaturated fatty acids لتقليل حدوث الالتهاب المعوي القولوني الناخر incidence of necrotizing enterocolitis |
| US6297279B1 (en) * | 1997-07-22 | 2001-10-02 | Nestac S.A. | Lipid composition for infant formula and method of preparation |
| US6294206B1 (en) * | 1999-04-09 | 2001-09-25 | Abbott Laboratories | Powdered human milk fortifier |
| US6596302B2 (en) * | 2000-04-13 | 2003-07-22 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof |
-
2001
- 2001-03-30 US US09/821,368 patent/US6596302B2/en not_active Expired - Lifetime
- 2001-03-30 US US09/821,010 patent/US6495599B2/en not_active Expired - Lifetime
- 2001-04-11 AR ARP010101740A patent/AR028331A1/es unknown
- 2001-04-12 CN CN01811142A patent/CN1436048A/zh active Pending
- 2001-04-12 KR KR1020027013687A patent/KR100793048B1/ko not_active IP Right Cessation
- 2001-04-12 JP JP2001575841A patent/JP2004518609A/ja not_active Withdrawn
- 2001-04-12 IL IL15197001A patent/IL151970A0/xx unknown
- 2001-04-12 AU AU2001255337A patent/AU2001255337A1/en not_active Abandoned
- 2001-04-12 EP EP01928487.6A patent/EP1272058B1/en not_active Revoked
- 2001-04-12 ES ES01928487.6T patent/ES2544853T3/es not_active Expired - Lifetime
- 2001-04-12 MX MXPA02010085A patent/MXPA02010085A/es active IP Right Grant
- 2001-04-12 WO PCT/US2001/011964 patent/WO2001078530A2/en not_active Application Discontinuation
- 2001-04-12 BR BR0107069-0A patent/BR0107069A/pt not_active IP Right Cessation
- 2001-04-12 CA CA002405822A patent/CA2405822C/en not_active Expired - Lifetime
- 2001-04-12 DK DK01928487.6T patent/DK1272058T3/da active
-
2002
- 2002-01-21 SA SA2220638A patent/SA02220638B1/ar unknown
- 2002-09-27 IL IL151970A patent/IL151970A/en active IP Right Grant
-
2003
- 2003-02-03 US US10/357,182 patent/US20030190363A1/en not_active Abandoned
- 2003-06-16 HK HK03104304.0A patent/HK1053247A1/xx not_active IP Right Cessation
-
2012
- 2012-02-20 JP JP2012033674A patent/JP2012144535A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL151970A0 (en) | 2003-04-10 |
| JP2004518609A (ja) | 2004-06-24 |
| IL151970A (en) | 2006-10-31 |
| US20020004527A1 (en) | 2002-01-10 |
| HK1053247A1 (en) | 2003-10-17 |
| MXPA02010085A (es) | 2003-10-15 |
| CA2405822A1 (en) | 2001-10-25 |
| WO2001078530A2 (en) | 2001-10-25 |
| KR20020090232A (ko) | 2002-11-30 |
| US20030190363A1 (en) | 2003-10-09 |
| BR0107069A (pt) | 2006-02-07 |
| EP1272058B1 (en) | 2015-06-24 |
| US6495599B2 (en) | 2002-12-17 |
| US20020045660A1 (en) | 2002-04-18 |
| SA02220638B1 (ar) | 2008-01-30 |
| WO2001078530A3 (en) | 2002-08-01 |
| JP2012144535A (ja) | 2012-08-02 |
| KR100793048B1 (ko) | 2008-01-10 |
| US6596302B2 (en) | 2003-07-22 |
| AU2001255337A8 (en) | 2005-09-08 |
| ES2544853T3 (es) | 2015-09-04 |
| AR028331A1 (es) | 2003-05-07 |
| EP1272058A2 (en) | 2003-01-08 |
| AU2001255337A1 (en) | 2001-10-30 |
| CA2405822C (en) | 2007-12-11 |
| CN1436048A (zh) | 2003-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1272058T3 (da) | Formuleringer til spædbørn indeholdende langkædede polyumættede fedtsyrer og anvendelser deraf | |
| Ryan et al. | Effect of DHA‐containing formula on growth of preterm infants to 59 weeks postmenstrual age | |
| JP5572645B2 (ja) | ドコサヘキサエン酸およびルテインを含有する乳児用製剤 | |
| Innis | Fatty acids and early human development | |
| Koletzko et al. | Physiological aspects of human milk lipids | |
| RU2670880C2 (ru) | Источник жиров растительного происхождения | |
| US9040075B2 (en) | Method of increasing lean body mass and reducing body fat mass in infants | |
| Gibson et al. | n− 3 Polyunsaturated fatty acid requirements of term infants | |
| Gibson et al. | The role of long chain polyunsaturated fatty acids (LCPUFA) in neonatal nutrition | |
| JP2011098966A (ja) | Ｐｕｆａサプリメント | |
| Vanderhoof et al. | Evaluation of a long-chain polyunsaturated fatty acid supplemented formula on growth, tolerance, and plasma lipids in preterm infants up to 48 weeks postconceptional age | |
| WO2008082946A1 (en) | Method of reducing the risk of retinophathy of prematurity in preterm infants | |
| Mathews et al. | Comparison of triglycerides and phospholipids as supplemental sources of dietary long-chain polyunsaturated fatty acids in piglets | |
| Luxwolda et al. | The relation between the omega-3 index and arachidonic acid is bell shaped: synergistic at low EPA+ DHA status and antagonistic at high EPA+ DHA status | |
| Forsyth | Lipids and infant formulas | |
| Rubin et al. | Effect of three intravenously administered fat emulsions containing different concentrations of fatty acids on the plasma fatty acid composition of premature infants | |
| EP4068991B1 (en) | Infant formula with special lipid architecture for improving postnatal growth of infants born by caesarean section | |
| Kuratko et al. | Enrichment of infant formula with omega-3 fatty acids | |
| Buta et al. | The Importance of Omega-3 Essential Fatty Acids in Pregnancy. Is the Vegan Diet Safe for Pregnant Women? | |
| Hernandez et al. | Applications of omega-3 fats in foods | |
| Mena et al. | 1.3. 5 Fats | |
| WO2023203156A1 (en) | Infant formula with special lipid architecture for reducing childhood blood pressure | |
| Hadders-Algra | Effect of Prenatal and Early Postnatal Nutritional Supplementation with Long-Chain Polyunsaturated Fatty Acids (LCPUFA) on Neurodevelopmental Outcome in Term Infants | |
| Goldman | The role of long chain polyunsaturated fatty acids in infant nutrition | |
| Koletzko et al. | 14 Role of Long-Chain |